Navigation Links
Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
Date:6/29/2010

SAINT PETERSBURG, June 29, 2010 /PRNewswire/ -- The Company VAM is the developer of product Glutoxim(R) registered in Russia in 1998, registration No. P N002010/01. We possess significant knowledge and experience in manufacturing of this product as well as in the clinical development application of Glutoxim(R). In accordance with an Agreement dated June 20, 2000, the company VAM diligently and successfully transferred all of the "know-how", manufacturing and quality assurance information on the active drug substance and finished injection forms of the product Glutoxim(R) to Novelos Therapeutics, Inc.

Up to October 2005, the active pharmaceutical ingredient used in Glutoxim(R) (US code name NOV002) was synthesized according to the original manufacturing process and technology transferred from the company VAM to Novelos. The original NOV002 (Glutoxim(R)) used in the Phase 1/2 NSCLC and all previous trials met predetermined clinical endpoints and yielded encouraging results.

After the completion of the Phase 3 NSCLC trial and learning that NOV002 had failed to meet clinical endpoints, VAM requested Novelos to provide samples of products used in the Phase 3 trial. At VAM's request, an independent chemical and biological analysis of the samples was performed in the State Technological Institute of Saint-Petersburg and State Research Trial Institute of Military Medicine.

Expert opinions - excerpts[1]

Technological Institute

"On the basis of data generated by the element analysis it is possible to make a conclusion, that all three presented dry samples considerably differ
'/>"/>

SOURCE Pharma Vam
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Hovione ... Ireland has successfully passed a pre-approval inspection by ... inspection, carried out by the FDA Consumer Safety Officer, Ms. ... started on 21 st July and concluded on the ... compliant with the principles and guidelines of Good Manufacturing Practices ...
(Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... in a Single Pill to Target Three Major ... Next Phase of Development, ABBOTT PARK, Ill. and ... will advance the development of,Abbott,s next-generation fenofibrate ABT-335 and ... Phase III,clinical trials. The single pill would target all ...
... Aug. 30 ,Palatin Technologies, Inc. (Amex: PTN ... announced today that they have delayed plans for ... a first in class,melanocortin agonist drug candidate, for ... follows responses from representatives of,the U.S. Food and ...
Cached Medicine Technology:Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 2Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 3King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
(Date:7/31/2014)... July 31, 2014 Ce-Classes.com has announced ... course for healthcare professionals, a Systematic Review of ... material published in the International Journal of Clinical and ... in response to a need to have accurate information ... the best treatment possible. The material provides a ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... type of disease, that requires insulin injections daily. Researchers ... this disease. Some medical research centers in the U.S. ... I diabetes by transplanting insulin-producing islet cells combined with ... live normal lives without insulin. , ...
... come up with a new technique of removing cancerous ... their hands and a special camera and instuments. This ... in significantly less time than the standard laproscopic procedure. ... of the American Urological Association by surgeons from the ...
... new gene which has the ability to slow down ... millions of people each year, and luckily tthe discovery ... the cancer of the colon, prostate,pancreas,brain and bowel. ... to stunt the cancer by starving the tumour ...
... from Mayo Clinic brings more choice in eating heath food// ... into any weight loss diets that restrict choices in food. ... the report that talks of sustainable eating habits that help ... weight requires a long-term commitment to making lifestyle changes. However, ...
... Researchers from UCLA had reported in the recent issue ... sleep suffer from loss of brain cells due to ... apnea, the person stops breathing during the sleep when ... in the brain as preB?tzinger complex (preB?tC), which is ...
... and its function has always left man dazzled for ... key factors// have been identified that could answer the ... babies and hence help treat prematurity. ,Identification ... brain damage repair in neurological diseases like multiple sclerosis ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Making operation and recovery time shorter 2Health News:New Healthy Weight Program Makes Healthy Eating More Interesting 2Health News:Sleep Apnea Related To Death And Loss Of Brain Cells 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: